Interferon-beta liquid formulations stabilized with a polyol, a
non-reducing sugar or a amino acid. In particular, the formulations are
stabilized with a polyol, such as mannitol. The formulations, preferably,
furthermore comprise a buffer, such as acetate buffer, at a pH comprised
between 3.0 and 4.0 and human albumin at a minimum quantity. The
interferon-beta is preferably recombinant.